Top

Cancer Immunology, Immunotherapy

Published in:

01-12-2018 | Original Article

Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies

Authors: Allison S. Dobry, Cheryl K. Zogg, F. Stephen Hodi, Timothy R. Smith, Patrick A. Ott, J. Bryan Iorgulescu

Published in: Cancer Immunology, Immunotherapy | Issue 12/2018

Abstract

Background

Immune checkpoint blockade (ICB) and BRAF^V600-targeted therapy have demonstrated substantial clinical efficacy for patients with stage 4 melanoma in clinical trials; however, their impact on survival and barriers to treatment in the “real-life” setting remains unknown.

Methods

Patients who presented with cutaneous melanoma during 2004–2015 using the National Cancer Database, which comprises > 70% of all newly diagnosed cancers in the U.S., were evaluated for predictors of presenting with stage 4 disease and receiving ICB, and for their associated unadjusted and risk-adjusted overall survival (OS).

Results

17,975 patients presented with stage 4 metastatic cutaneous melanoma. Overall, patients who presented after the FDA’s initial approvals (starting in 2011) for ICB and BRAF^V600-targeted therapy demonstrated a 31% relative improvement in 4-year OS (p < 0.001), compared to pre-2011. Following the initial approvals in 2011, improved OS was associated in risk-adjusted analyses with ICB (HR 0.57, 95CI 0.52–0.63). ICB demonstrated improved median and 4-year OS of 16.9 months (95CI 15.6–19.3; vs. 7.7 months, 95CI 7.2–8.4) and 32.4% (95CI 29.5–35.3; vs. 21.0%, 95CI 19.6–22.2, all p < 0.001), respectively; improved OS was persistent in unadjusted and risk-adjusted landmark survival analyses. Uninsured patients and management in the community setting were less likely to receive ICB in multivariable analyses.

Conclusions

In a national “real-life” treatment population, we show that the wide availability of the novel treatment modalities ICB and BRAF^V600-targeted therapy has significantly improved the survival of patients with stage 4 melanoma. Our findings additionally suggest that there are opportunities for expanding coverage and access to these novel immunotherapies in community practice.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332 CrossRefPubMed

Glazer AM, Winkelmann RR, Farberg AS, Rigel DS (2017) Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol 153:225–226. https://doi.org/10.1001/jamadermatol.2016.4512 CrossRefPubMed

Eggermont AM, Spatz A, Robert C (2014) Cutaneous melanoma. Lancet 383:816–827. https://doi.org/10.1016/S0140-6736(13)60802-8 CrossRefPubMed

Force J, Salama AK (2017) First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets Ther 6:1–10. https://doi.org/10.2147/ITT.S110479 CrossRefPubMedPubMedCentral

Ascierto PA, McArthur GA, Dréno B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260. https://doi.org/10.1016/S1470-2045(16)30122-X CrossRefPubMed

Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714. https://doi.org/10.1056/NEJMoa1112302 CrossRefPubMedPubMedCentral

Dummer R, Ascierto PA, Gogas HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603–615. https://doi.org/10.1016/S1470-2045(18)30142-6 CrossRefPubMed

Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309. https://doi.org/10.1158/1078-0432.CCR-13-0143 CrossRefPubMed

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

10.

Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155–164. https://doi.org/10.1016/S1470-2045(09)70334-1 CrossRefPubMed

11.

Ascierto PA, Del Vecchio M, Robert C et al (2017) Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 18:611–622. https://doi.org/10.1016/S1470-2045(17)30231-0 CrossRefPubMed

12.

Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. https://doi.org/10.1056/NEJMoa1503093 CrossRefPubMed

13.

Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017. https://doi.org/10.1056/NEJMoa1414428 CrossRefPubMedPubMedCentral

14.

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. https://doi.org/10.1056/NEJMoa1504030 CrossRefPubMedPubMedCentral

15.

Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356. https://doi.org/10.1056/NEJMoa1709684 CrossRefPubMedPubMedCentral

16.

Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. https://doi.org/10.1056/NEJMoa1103782 CrossRefPubMedPubMedCentral

17.

Long GV, Stroyakovskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444–451. https://doi.org/10.1016/S0140-6736(15)60898-4 CrossRefPubMed

18.

Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877–1888. https://doi.org/10.1056/NEJMoa1406037 CrossRefPubMed

19.

Larkin J, Ascierto PA, Dréno B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876. https://doi.org/10.1056/NEJMoa1408868 CrossRefPubMed

20.

Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39. https://doi.org/10.1056/NEJMoa1412690 CrossRefPubMed

21.

National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology: Melanoma version 2.2018. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#melanoma. Accessed 1 Mar 2018

22.

Larkin J, Lao CD, Urba WJ et al (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1:433–440. https://doi.org/10.1001/jamaoncol.2015.1184 CrossRefPubMed

23.

Atkins MB, Larkin J (2016) Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. J Natl Cancer Inst 108:414. https://doi.org/10.1093/jnci/djv414 CrossRef

24.

Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918. https://doi.org/10.1016/S1470-2045(15)00083-2 CrossRefPubMedPubMedCentral

25.

Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384. https://doi.org/10.1016/S1470-2045(15)70076-8 CrossRefPubMed

26.

Weber JS, Gibney G, Sullivan RJ et al (2016) Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 17:943–955. https://doi.org/10.1016/S1470-2045(16)30126-7 CrossRefPubMedPubMedCentral

27.

Hodi FS, Chesney J, Pavlick AC et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558–1568. https://doi.org/10.1016/S1470-2045(16)30366-7 CrossRefPubMedPubMedCentral

28.

Pasquali S, Chiarion-Sileni V, Rossi CR, Mocellin S (2017) Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis. Cancer Treat Rev 54:34–42. https://doi.org/10.1016/j.ctrv.2017.01.006 CrossRefPubMed

29.

Boffa DJ, Rosen JE, Mallin K et al (2017) Using the national cancer database for outcomes research: a review. JAMA Oncol 3:1722–1728. https://doi.org/10.1001/jamaoncol.2016.6905 CrossRefPubMed

30.

LeBoit PE, Burg G, Weedon D, Sarasain A (2006) Pathology and genetics of skin tumours, 3rd edn. IARC Press, Lyon

31.

Iorgulescu JB, Harary M, Zogg CK et al (2018) Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res 6:1–7. https://doi.org/10.1158/2326-6066.CIR-18-0067 CrossRef

32.

Shaikh WR, Dusza SW, Weinstock MA et al (2016) Melanoma thickness and survival trends in the United States, 1989–2009. J Natl Cancer Inst 108:1. https://doi.org/10.1093/jnci/djv294 CrossRef

33.

Howard JH, Thompson JF, Mozzillo N et al (2012) Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 19:2547–2555. https://doi.org/10.1245/s10434-012-2398-z CrossRefPubMedPubMedCentral

34.

Barker CA, Postow MA (2014) Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986–997. https://doi.org/10.1016/j.ijrobp.2013.08.035 CrossRefPubMedPubMedCentral

35.

Joosse A, de Vries E, Eckel R et al (2011) Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Investig Dermatol 131:719–726. https://doi.org/10.1038/jid.2010.354 CrossRefPubMed

Title: Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
Authors: Allison S. Dobry
Cheryl K. Zogg
F. Stephen Hodi
Timothy R. Smith
Patrick A. Ott
J. Bryan Iorgulescu
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 12/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2241-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2018

Personalized cancer vaccines: adjuvants are important, too

The role of CCR5 in directing the mobilization and biological function of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells in cancer

Targeting CTCFL/BORIS for the immunotherapy of cancer

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

Dendritic cell trafficking in tumor-bearing mice

Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer